Supplementary Material to Mahlangu et al. “Long-acting recombinant factor VIII Fc fusion protein (rFVIIIFc) for perioperative haemostatic management in severe haemophilia A” (Thromb Haemost 2016; 116.1)

Suppl. Figure 1. Surgical dosing regimen and FVIII activity over time for three representative subjects: (A) Subject 1, (B) Subject 12, and (C) Subject 16. All local FVIII activity measurements and doses of rFVIIIFc for surgery were included and plotted at the time of assessment and administration, respectively. Data points indicate FVIII activity over time as measured by the local laboratory. FVIII activity measurements taken within an hour before a dose of rFVIIIFc were categorised as a trough measurement. FVIII activity measurements taken within an hour after a dose of rFVIIIFc were categorised as a peak measurement. FVIII activity measurements taken at other times were categorised as “other FVIII activity measurements.” Arrows at the top of the plot indicate timing and actual dose in IU/kg.

A.

![Graph showing surgical dosing regimen and FVIII activity over time for three representative subjects. The graph includes data points indicating FVIII activity over time as measured by the local laboratory, with arrows at the top indicating timing and actual dose in IU/kg.](image-url)
B. 

Subject 1 underwent arthrodesis of the tibiotalar and subtalar joint, was enrolled in ASPIRE 269 days prior to surgery, and received an initial rFVIIIFc prophylaxis regimen of ~65 IU/kg once weekly prior to surgery. No adverse events or serious adverse events were reported during the postoperative period.

C. 

Subject 12 underwent a right hip arthroplasty, was enrolled in ASPIRE 43 days prior to surgery, and received an initial rFVIIIFc prophylaxis regimen of ~50 IU/kg every three days prior to surgery. Nonserious adverse events of fever, anemia, and increased platelet count were reported during the postoperative period that all resolved; no serious adverse events were reported.

Subject 16 underwent a left total knee arthroplasty, was enrolled in ASPIRE 176 days prior to surgery, and received an initial rFVIIIFc prophylaxis regimen of ~50 IU/kg every five days prior to surgery. A nonserious adverse event of fever was reported during the postoperative period that was resolved; no serious adverse events were reported.

FVIII, factor VIII; rFVIIIFc, recombinant factor VIII Fc fusion protein. aSubject 1 underwent arthrodesis of the tibiotalar and subtalar joint, was enrolled in ASPIRE 269 days prior to surgery, and received an initial rFVIIIFc prophylaxis regimen of ~65 IU/kg once weekly prior to surgery. No adverse events or serious adverse events were reported during the postoperative period. bSubject 12 underwent a right hip arthroplasty, was enrolled in ASPIRE 43 days prior to surgery, and received an initial rFVIIIFc prophylaxis regimen of ~50 IU/kg every three days prior to surgery. Nonserious adverse events of fever, anemia, and increased platelet count were reported during the postoperative period that all resolved; no serious adverse events were reported. cSubject 16 underwent a left total knee arthroplasty, was enrolled in ASPIRE 176 days prior to surgery, and received an initial rFVIIIFc prophylaxis regimen of ~50 IU/kg every five days prior to surgery. A nonserious adverse event of fever was reported during the postoperative period that was resolved; no serious adverse events were reported.